GE gets FDA priority review for imaging agent
Thursday, June 12, 2008 - 14:14
in Health & Medicine
CHICAGO (Reuters) - GE Healthcare, a unit of General Electric Corp, said on Thursday U.S. health regulators granted it priority review on its application for AdreView, a molecular imaging agent for the detection of neuroendocrine tumors in children and adult patients.
Read the whole article on Reuters:Science
More from Reuters:Science
Related
- Bevacizumab better than gold standard imaging at detecting tumorsWed, 22 Oct 2008, 8:22:19 EDT
- New technique images tumor vessel leakiness to predict breast cancer chemotherapy outcomeMon, 2 Feb 2009, 5:07:58 EST
- Researchers create smaller, brighter probe tailored for molecular imaging and tumor targetingMon, 22 Dec 2008, 17:22:31 EST
- Global priority regions for carnivore conservationSat, 29 Aug 2009, 1:39:21 EDT
- Patients will face delays in getting diagnostic scans due to severe shortage of imaging agentsFri, 5 Sep 2008, 19:28:56 EDT